TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26931143

Group type: EXPERIMENTAL
Intervention: Obese mothers
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mothers
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Overweight and/or obese mothers
Number of subjects: 331

Group type: COMPARATOR
Intervention: Healthy normal weight controls
Number of subjects: 331
Study: 26931156

Group type: EXPERIMENTAL
Intervention: Thrombectomy with or without preceding thrombolysis
Number of subjects: 28
Study: 26931475

Group type: EXPERIMENTAL
Intervention: Infused angiotensin II (LJPC-501)
Number of subjects: 0
Study: 26931738

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention for hypertension
Number of subjects: 0
Study: 26932146

Group type: EXPERIMENTAL
Intervention: DMF 240 mg BID
Number of subjects: 229

Group type: COMPARATOR
Intervention: PBO for 2 years followed by DMF 240 mg BID for 4 years
Number of subjects: 229
Study: 26932276

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Nonaspirin
Number of subjects: 406
Study: 26932848

Group type: EXPERIMENTAL
Intervention: Group phone-based weight loss intervention
Number of subjects: 186
Study: 26933082

Group type: COMPARATOR
Intervention: Acute Ischemic Stroke (AIS) patients
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Non-ST-segment-elevation acute coronary syndrome (NSTE-ACS) patients
Number of subjects: 29
Study: 26933421

Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platinum doublets
Number of subjects: 0
Study: 26933422

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1 inhibitor) and RRx-001 (experimental anticancer agent)
Number of subjects: 1
Study: 26933507

Group type: EXPERIMENTAL
Intervention: AZD8848 (inhalation dosing)
Number of subjects: 0
Study: 26934062

Group type: EXPERIMENTAL
Intervention: Paliperidone (extended-release oral formulation and long-acting injectable once-monthly paliperidone palmitate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paliperidone (monotherapy or adjunctively with antidepressants or mood stabilizers)
Number of subjects: 0
Study: 26934141

Group type: EXPERIMENTAL
Intervention: FLIO (Fluorescence Lifetime Imaging Ophthalmoscopy)
Number of subjects: 16
Study: 26934345

Group type: EXPERIMENTAL
Intervention: Ipilimumab therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ipilimumab/Nivolumab combination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: T-VEC therapy
Number of subjects: 100
Study: 26934750

Group type: EXPERIMENTAL
Intervention: Anflu® vaccine (2013-14 formulation: H1N1, H3N2, BYAM)
Number of subjects: 182
Study: 26935225

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasonography (POCUS)
Number of subjects: 103
Study: 26936878

Group type: EXPERIMENTAL
Intervention: Double pumping
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single pumping
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Expressing 500 mL/day by day 10
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Breast pump comfort (best)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Breast pump comfort (middle)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Breast pump comfort (worst)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Number of episodes of 'breast feeding'
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Number of complete daily records
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Use of double versus single pumping
Number of subjects: 62
Study: 26937680

Group type: EXPERIMENTAL
Intervention: Femtosecond lenticule extraction (FLEx)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Small-incision lenticule extraction (SMILE)
Number of subjects: 41
Study: 26937681

Group type: EXPERIMENTAL
Intervention: Nonlinear analysis of respiratory biosignals (Largest Lyapunov Exponent, Detrended Fluctuation Analysis, Approximate Entropy) and linear analysis from Oxygen saturation for predicting Apnea-Hypopnea Index (AHI).
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Linear regression model for predicting AHI.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Decision tree for discrimination between patients and normal subjects.
Number of subjects: 135
Study: 26938078

Group type: EXPERIMENTAL
Intervention: Triple therapy with first generation protease inhibitors (n = 23)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dual therapy with peginterferon and ribavirin (n = 21)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Triple therapy with first generation protease inhibitors
Number of subjects: 108
Study: 26938617

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 10
Study: 26938769

Group type: EXPERIMENTAL
Intervention: Inverting filter that undoes the effects of a 0.05 Hz single pole high-pass filter
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Alternative, less strong inverting filters
Number of subjects: 1600
Study: 26939629

Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery treatment of a therapeutic antibody
Number of subjects: 6
Study: 26940080

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered as a bolus of 1 μg/kg over 10 min followed by 1 μg/kg/h infusion, with possible increase to 2 μg/kg/h if necessary.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lower dexmedetomidine dose and shorter sedation time for children younger than 1 year of age.
Number of subjects: 19
Study: 26940214

Group type: EXPERIMENTAL
Intervention: High SBP
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: BPRS-0
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: BPRS-2
Number of subjects: 455
Study: 26940383

Group type: EXPERIMENTAL
Intervention: Early home-based walking program implemented 1-month post-ICD implant.
Number of subjects: 301
Study: 26940556

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 9500

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 9500

Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 9500
Study: 26940814

Group type: EXPERIMENTAL
Intervention: Home ventilation for complex children
Number of subjects: 90
Study: 26940919

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores >400
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Low CAC scores in white women
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Subclinical cardiovascular disease measures (CAC, carotid intimal medial thickness, stenosis, ankle brachial index)
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Dementia diagnosis prior to death
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Overall incidence of dementia
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Deaths caused by CHD
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Deaths caused by dementia
Number of subjects: 532
Study: 26941415

Group type: EXPERIMENTAL
Intervention: Decreased left atrial reservoir strain
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Left atrial reservoir strain
Number of subjects: 308
Study: 26941952

Group type: COMPARATOR
Intervention: Standard decision aid (control)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Regret-incorporated decision aid (experimental)
Number of subjects: 184
Study: 26942366

Group type: EXPERIMENTAL
Intervention: C sordellii presence
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: C perfringens presence
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: C sordellii follow-up
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: C perfringens follow-up
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: Recent gynecologic surgery
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: High body mass index
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: C sordellii isolates
Number of subjects: 4152

Group type: EXPERIMENTAL
Intervention: Strain diversity
Number of subjects: 4152
Study: 26942463

Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg orally once daily
Number of subjects: 25
Study: 26942886

Group type: EXPERIMENTAL
Intervention: Matched cohort (received no drugs predicted to be lack-of-benefit)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Unmatched cohort (received at least one drug predicted to be lack-of-benefit)
Number of subjects: 224
Study: 26943275

Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel chemotherapy
Number of subjects: 40
Study: 26943915

Group type: EXPERIMENTAL
Intervention: S-AR-42 administered via intravenous and oral routes in rodents
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: R-AR-42 administered intravenously in rats
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: S-AR-42 administered orally to tumor-bearing mice
Number of subjects: 2
Study: 26944198

Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy
Number of subjects: 50
Study: 26944482

Group type: EXPERIMENTAL
Intervention: Digitally mediated personal physician presence (facilitated access to the alcohol-reduction website)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 620
Study: 26944694

Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters recorded using sublingual incident dark field microscopy and global flow measurements (oesophageal Doppler and transthoracic echocardiography).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment scores analysis.
Number of subjects: 0
Study: 26944863

Group type: EXPERIMENTAL
Intervention: Oral LNG 1.5 mg plus LNG 52 mg IUD
Number of subjects: 188

Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 188
Study: 26945556

Group type: EXPERIMENTAL
Intervention: Colonic confocal laser endomicroscopy (CLE) after medical treatment escalation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Inactive ulcerative colitis and control subjects
Number of subjects: 29
Study: 26945673

Group type: EXPERIMENTAL
Intervention: Genetic and psychological factors (KCNS1 and kinesiophobia)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Genetic and psychological factors (ADRB2 and depressive symptoms)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Genetic and psychological factors (GCH1 and anxiety symptoms)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inflammatory genes (IL6 SNPs and pain catastrophizing)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inflammatory genes (IL6 and depressive symptoms)
Number of subjects: 150
Study: 26945843

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra) + low-dose dexamethasone (20 mg weekly)
Number of subjects: 47
Study: 26946139

Group type: EXPERIMENTAL
Intervention: Automatic segmentation of myocardium at risk (MaR) using contrast enhanced SSFP (CE-SSFP)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Manual delineation of myocardium at risk (MaR)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Automatic segmentation of MaR using CE-SSFP
Number of subjects: 183

Group type: COMPARATOR
Intervention: Manual delineation
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Automatic segmentation
Number of subjects: 183
Study: 26946290

Group type: EXPERIMENTAL
Intervention: LDL-C (one standard deviation increase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMGCR (positive control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCSK9, APOB, LPA, CETP, PLG, NPC1L1, ALDH2 (identified druggable loci)
Number of subjects: 0
Study: 26946891

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound (DU)
Number of subjects: 66
Study: 26947173

Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warfarin (25 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Roxadustat and Warfarin
Number of subjects: 20
Study: 26947199

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day, days 1-21 of a 28-day cycle (cohort 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day continuously (cohort 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lenalidomide 35 mg/day continuously (cohort 3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Lenalidomide (all cohorts)
Number of subjects: 14
Study: 26947376

Group type: EXPERIMENTAL
Intervention: Caudal traction of ipsilateral arm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Abduction of ipsilateral arm
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caudal traction of ipsilateral arm in adults
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral position of ipsilateral arm
Number of subjects: 60
Study: 26947564

Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Vaniprevir treatment
Number of subjects: 79
Study: 26948580

Group type: EXPERIMENTAL
Intervention: 140 mg semagacestat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 280 mg semagacestat
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26948683

Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone suppression test (DST)
Number of subjects: 278
Study: 26949046

Group type: EXPERIMENTAL
Intervention: Metabolic phenotyping of plasma
Number of subjects: 233
Study: 26949390

Group type: EXPERIMENTAL
Intervention: Continuous S(+)-ketamine infusion at a rate of 0.3 mg·kg(-1)·h(-1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (saline at the same rate)
Number of subjects: 48
Study: 26950065

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 2433

Group type: EXPERIMENTAL
Intervention: Daily recombinant follicle stimulation hormone (rFSH)
Number of subjects: 2433

Group type: COMPARATOR
Intervention: Control group (GnRH agonist protocol)
Number of subjects: 2433

Group type: EXPERIMENTAL
Intervention: hCG administration
Number of subjects: 2433

Group type: EXPERIMENTAL
Intervention: Combination of follicles ≥ 11 mm and E2 levels
Number of subjects: 2433
Study: 26951043

Group type: EXPERIMENTAL
Intervention: RebiSmart(®) for self-administering IFN β-1a 44 μg three times weekly
Number of subjects: 162
Study: 26951310

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study: 26951396

Group type: EXPERIMENTAL
Intervention: Orexin-A
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 63
Study: 26951410

Group type: EXPERIMENTAL
Intervention: Depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Self-reported nocturnal hot flashes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Objective hot flashes
Number of subjects: 28
Study: 26951627

Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg once daily) combined with chemotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Dasatinib-based protocol
Number of subjects: 51
Study: 26951635

Group type: EXPERIMENTAL
Intervention: GlycA (circulating N-acetyl glycan groups)
Number of subjects: 27524
Study: 26951820

Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 Gag/Pol/Nef vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26951967

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study: 26952006

Group type: EXPERIMENTAL
Intervention: Resminostat plus sorafenib (n=38); dosages ranged from daily 200 to 600mg resminostat plus 400 to 800mg sorafenib.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Resminostat monotherapy (n=19); dosage was 600mg.
Number of subjects: 57
Study: 26952546

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg, given every 3 weeks)
Number of subjects: 310
Study: 26953688

Group type: EXPERIMENTAL
Intervention: Inhibition processes
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Updating processes
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Shifting processes
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Inhibition capacity
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Nicotine dependence level
Number of subjects: 134
Study: 26953733

Group type: EXPERIMENTAL
Intervention: Women aged 34-35 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women aged 36-37 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women aged 38-39 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women aged 40-41 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women aged 42-44 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women aged 30-31 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women with no prior pregnancy
Number of subjects: 0
Study: 26953848

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W
Number of subjects: 3866

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 3866

Group type: COMPARATOR
Intervention: Ixekizumab (both doses)
Number of subjects: 3866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3866
Study: 26954903

Group type: EXPERIMENTAL
Intervention: Pain measures using Brief Pain Inventory Short Form (BPI-SF) and Short Form McGill Pain Questionnaire (SF-MPQ)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test (SNOT-22)
Number of subjects: 70
Study: 26956588

Group type: EXPERIMENTAL
Intervention: Intervention Measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 26956723

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 25
Study: 26957354

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral relaxation program
Number of subjects: 0
Study: 26957532

Group type: EXPERIMENTAL
Intervention: Evidence-based medication use in-hospital and at discharge
Number of subjects: 76141

Group type: EXPERIMENTAL
Intervention: Predicted 6-month mortality
Number of subjects: 76141

Group type: EXPERIMENTAL
Intervention: Observed 6-month mortality
Number of subjects: 76141

Group type: EXPERIMENTAL
Intervention: Post-myocardial infarction mortality
Number of subjects: 76141
Study: 26958364

Group type: EXPERIMENTAL
Intervention: Multibiomarker disease activity (MBDA) score
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Low MBDA score
Number of subjects: 220
Study: 26960231

Group type: EXPERIMENTAL
Intervention: Machine learning scheme using mean diffusivity (MD) features and linear kernel SVMs
Number of subjects: 40
Study: 26960790

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 0
Study: 26960977

Group type: EXPERIMENTAL
Intervention: 20 mg adenosine injected into the left atrium
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 12 mg adenosine injected sequentially after 20 mg
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 6 mg adenosine injected sequentially after 20 mg
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: High-dose adenosine
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Exit block test
Number of subjects: 378
Study: 26961146

Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg monotherapy twice daily (capsule formulation)
Number of subjects: 300
Study: 26961303

Group type: EXPERIMENTAL
Intervention: True Bipolar LV pacing
Number of subjects: 969

Group type: COMPARATOR
Intervention: Unipolar/Extended Bipolar LV pacing
Number of subjects: 969
Study: 26961932

Group type: EXPERIMENTAL
Intervention: Lifestyle counseling or bariatric surgery
Number of subjects: 184
Study: 26962015

Group type: EXPERIMENTAL
Intervention: Living with a smoker
Number of subjects: 1580

Group type: EXPERIMENTAL
Intervention: Second-hand smoke exposure in the past week
Number of subjects: 1580
Study: 26962173

Group type: EXPERIMENTAL
Intervention: Protein intake of 0.2 to 2.0 g ⋅ kg-1 ⋅ d-1, consumed hourly for 8 hours as an amino acid mixture with egg protein and L-[1-13C]phenylalanine as the indicator amino acid.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Current intake recommendations for dietary protein of 0.66 g ⋅ kg-1 ⋅ d-1 for EAR and 0.8 g ⋅ kg-1 ⋅ d-1 for RDA.
Number of subjects: 6
Study: 26962176

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) quartile 4
Number of subjects: 6542

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) quartile 4 in low-to-moderate alcohol drinkers
Number of subjects: 6542
Study: 26962179

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 restriction (0.37 ± 0.04 mg/d)
Number of subjects: 23
Study: 26962183

Group type: EXPERIMENTAL
Intervention: α-lipoic acid (LA) 0.3 g/d
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.3 g/d
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 73
Study: 26962189

Group type: EXPERIMENTAL
Intervention: Cocoa extract (1.4 g/d, 645 mg total polyphenols/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no cocoa supplementation)
Number of subjects: 47
Study: 26962193

Group type: EXPERIMENTAL
Intervention: SQ-LNSs with 0 or 10 mg added zinc and placebo tablet
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Control group (NIC)
Number of subjects: 2435
Study: 26962194

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (n = 104)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control diet (n = 96)
Number of subjects: 200
Study: 26963600

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Behavior Therapy (BT)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 188
Study: 26964824

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26965168

Group type: EXPERIMENTAL
Intervention: Elective admission (88 patients)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Non-elective admission (90 patients)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Elective admission
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Correlation with APACHE IV score
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Presence of infection
Number of subjects: 178

Group type: COMPARATOR
Intervention: Type of admission
Number of subjects: 178